{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:06:09Z","timestamp":1790867169475,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,11,29]],"date-time":"2009-11-29T00:00:00Z","timestamp":1259452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s00262-009-0794-4","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T06:58:21Z","timestamp":1259391501000},"page":"737-746","source":"Crossref","is-referenced-by-count":21,"title":["Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin"],"prefix":"10.1007","volume":"59","author":[{"given":"Robert","family":"Sarnovsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Tendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheusz","family":"Makowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Kiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Antignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Traini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,29]]},"reference":[{"key":"794_CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA (2007) Trastuzumab\u2014mechanism of action and use in clinical practice. N Engl J Med 357:39\u201351","journal-title":"N Engl J Med"},{"key":"794_CR2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","volume":"359","author":"BD Cheson","year":"2008","unstructured":"Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma. N Engl J Med 359:613\u2013626","journal-title":"N Engl J Med"},{"key":"794_CR3","doi-asserted-by":"crossref","unstructured":"Heimann DM, Weiner LM (2007) Monoclonal antibodies in therapy of solid tumors. Surg Oncol Clin N Am 16:775\u2013792, viii","DOI":"10.1016\/j.soc.2007.07.001"},{"key":"794_CR4","doi-asserted-by":"crossref","first-page":"5598s","DOI":"10.1158\/1078-0432.CCR-07-1223","volume":"13","author":"DJ Green","year":"2007","unstructured":"Green DJ, Pagel JM, Pantelias A et al (2007) Pretargeted radioimmunotherapy for B-cell lymphomas. Clin Cancer Res 13:5598s\u20135603s","journal-title":"Clin Cancer Res"},{"key":"794_CR5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2174\/138920108784567272","volume":"9","author":"SM Rybak","year":"2008","unstructured":"Rybak SM (2008) Antibody\u2013onconase conjugates: cytotoxicity and intracellular routing. Curr Pharm Biotechnol 9:226\u2013230","journal-title":"Curr Pharm Biotechnol"},{"key":"794_CR6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-065X.2008.00601.x","volume":"222","author":"XY Liu","year":"2008","unstructured":"Liu XY, Pop LM, Vitetta ES (2008) Engineering therapeutic monoclonal antibodies. Immunol Rev 222:9\u201327","journal-title":"Immunol Rev"},{"key":"794_CR7","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.2174\/092986708785132997","volume":"15","author":"Y Singh","year":"2008","unstructured":"Singh Y, Palombo M, Sinko PJ (2008) Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 15:1802\u20131826","journal-title":"Curr Med Chem"},{"key":"794_CR8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/17425247.5.1.87","volume":"5","author":"MJ Brumlik","year":"2008","unstructured":"Brumlik MJ, Daniel BJ, Waehler R et al (2008) Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. Expert Opin Drug Deliv 5:87\u2013103","journal-title":"Expert Opin Drug Deliv"},{"key":"794_CR9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PPO.0b013e318172d704","volume":"14","author":"PJ Carter","year":"2008","unstructured":"Carter PJ, Senter PD (2008) Antibody\u2013drug conjugates for cancer therapy. Cancer J 14:154\u2013169","journal-title":"Cancer J"},{"key":"794_CR10","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1038\/sj.onc.1210373","volume":"26","author":"DM Goldenberg","year":"2007","unstructured":"Goldenberg DM, Sharkey RM (2007) Novel radiolabeled antibody conjugates. Oncogene 26:3734\u20133744","journal-title":"Oncogene"},{"key":"794_CR11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.med.58.070605.115320","volume":"58","author":"I Pastan","year":"2007","unstructured":"Pastan I, Hassan R, FitzGerald DJ et al (2007) Immunotoxin treatment of cancer. Annu Rev Med 58:221\u2013237","journal-title":"Annu Rev Med"},{"key":"794_CR12","doi-asserted-by":"crossref","unstructured":"Kreitman RJ, Pastan I (2006) Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol Oncol Clin North Am 20:1137\u20131151, viii","DOI":"10.1016\/j.hoc.2006.06.009"},{"key":"794_CR13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/ncponc0774","volume":"4","author":"AD Ricart","year":"2007","unstructured":"Ricart AD, Tolcher AW (2007) Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 4:245\u2013255","journal-title":"Nat Clin Pract Oncol"},{"key":"794_CR14","first-page":"326","volume":"6","author":"AE Frankel","year":"2000","unstructured":"Frankel AE, Kreitman RJ, Sausville EA (2000) Targeted toxins. Clin Cancer Res 6:326\u2013334","journal-title":"Clin Cancer Res"},{"key":"794_CR15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0093-7754(03)00241-0","volume":"30","author":"AE Frankel","year":"2003","unstructured":"Frankel AE, Neville DM, Bugge TA et al (2003) Immunotoxin therapy of hematologic malignancies. Semin Oncol 30:545\u2013557","journal-title":"Semin Oncol"},{"key":"794_CR16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","volume":"6","author":"I Pastan","year":"2006","unstructured":"Pastan I, Hassan R, Fitzgerald DJ et al (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559\u2013565","journal-title":"Nat Rev Cancer"},{"key":"794_CR17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/annonc\/mdg209","volume":"14","author":"R Schnell","year":"2003","unstructured":"Schnell R, Borchmann P, Staak JO et al (2003) Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin\u2019s lymphoma. Ann Oncol 14:729\u2013736","journal-title":"Ann Oncol"},{"key":"794_CR18","first-page":"1779","volume":"8","author":"R Schnell","year":"2002","unstructured":"Schnell R, Staak O, Borchmann P (2002) A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma. Clin Cancer Res 8:1779\u20131786","journal-title":"Clin Cancer Res"},{"key":"794_CR19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1078-0432.CCR-1216-3","volume":"10","author":"AE Frankel","year":"2004","unstructured":"Frankel AE (2004) Reducing the immune response to immunotoxin. Clin Cancer Res 10:13\u201315","journal-title":"Clin Cancer Res"},{"key":"794_CR20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/bcr1284","volume":"7","author":"D Messmer","year":"2005","unstructured":"Messmer D, Kipps TJ (2005) Treatment of solid tumors with immunotoxins. Breast Cancer Res 7:184\u2013186","journal-title":"Breast Cancer Res"},{"key":"794_CR21","doi-asserted-by":"crossref","first-page":"11311","DOI":"10.1073\/pnas.0804851105","volume":"105","author":"M Onda","year":"2008","unstructured":"Onda M, Beers R, Xiang L et al (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105:11311\u201311316","journal-title":"Proc Natl Acad Sci USA"},{"key":"794_CR22","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.4049\/jimmunol.177.12.8822","volume":"177","author":"M Onda","year":"2006","unstructured":"Onda M, Nagata S, FitzGerald DJ et al (2006) Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 177:8822\u20138834","journal-title":"J Immunol"},{"key":"794_CR23","first-page":"3092","volume":"8","author":"JA Posey","year":"2002","unstructured":"Posey JA, Khazaeli MB, Bookman MA et al (2002) A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 8:3092\u20133099","journal-title":"Clin Cancer Res"},{"key":"794_CR24","doi-asserted-by":"crossref","unstructured":"Weldon JE, Xiang L, Chertov O et al (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 113(16):3792\u20133800","DOI":"10.1182\/blood-2008-08-173195"},{"key":"794_CR25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","volume":"345","author":"RJ Kreitman","year":"2001","unstructured":"Kreitman RJ, Wilson WH, Bergeron K et al (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241\u2013247","journal-title":"N Engl J Med"},{"key":"794_CR26","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","volume":"13","author":"R Hassan","year":"2007","unstructured":"Hassan R, Bullock S, Premkumar A et al (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144\u20135149","journal-title":"Clin Cancer Res"},{"key":"794_CR27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1078-0432.CCR-1160-3","volume":"10","author":"R Hassan","year":"2004","unstructured":"Hassan R, Williams-Gould J, Watson T et al (2004) Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 10:16\u201318","journal-title":"Clin Cancer Res"},{"key":"794_CR28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1098\/rstb.2001.0839","volume":"356","author":"SJ Knechtle","year":"2001","unstructured":"Knechtle SJ (2001) Treatment with immunotoxin. Philos Trans R Soc Lond B Biol Sci 356:681\u2013689","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"794_CR29","first-page":"7750","volume":"50","author":"LH Pai","year":"1990","unstructured":"Pai LH, FitzGerald DJ, Tepper M et al (1990) Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 50:7750\u20137753","journal-title":"Cancer Res"},{"key":"794_CR30","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1074\/jbc.M710008200","volume":"283","author":"R Jorgensen","year":"2008","unstructured":"Jorgensen R, Purdy AE, Fieldhouse RJ et al (2008) Cholix toxin, a novel ADP-ribosylating factor from Vibrio cholerae. J Biol Chem 283:10671\u201310678","journal-title":"J Biol Chem"},{"key":"794_CR31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1128\/IAI.59.1.407-414.1991","volume":"59","author":"M Ogata","year":"1991","unstructured":"Ogata M, Pastan I, FitzGerald D (1991) Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes. Infect Immun 59:407\u2013414","journal-title":"Infect Immun"},{"key":"794_CR32","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1128\/MCB.11.4.2200","volume":"11","author":"JK Batra","year":"1991","unstructured":"Batra JK, Fitzgerald DJ, Chaudhary VK et al (1991) Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol Cell Biol 11:2200\u20132205","journal-title":"Mol Cell Biol"},{"key":"794_CR33","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1128\/JB.187.9.2992-3001.2005","volume":"187","author":"A Purdy","year":"2005","unstructured":"Purdy A, Rohwer F, Edwards R et al (2005) A glimpse into the expanded genome content of Vibrio cholerae through identification of genes present in environmental strains. J Bacteriol 187:2992\u20133001","journal-title":"J Bacteriol"},{"key":"794_CR34","first-page":"682","volume":"10","author":"J Buchner","year":"1992","unstructured":"Buchner J, Brinkmann U, Pastan I (1992) Renaturation of a single-chain immunotoxin facilitated by chaperones and protein disulfide isomerase. Biotechnology (N Y) 10:682\u2013685","journal-title":"Biotechnology (N Y)"},{"key":"794_CR35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0003-2697(92)90433-8","volume":"205","author":"J Buchner","year":"1992","unstructured":"Buchner J, Pastan I, Brinkmann U (1992) A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 205:263\u2013270","journal-title":"Anal Biochem"},{"key":"794_CR36","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","volume":"18","author":"RJ Kreitman","year":"2000","unstructured":"Kreitman RJ, Wilson WH, White JD et al (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622\u20131636","journal-title":"J Clin Oncol"},{"key":"794_CR37","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1128\/JCM.33.10.2715-2722.1995","volume":"33","author":"A Dalsgaard","year":"1995","unstructured":"Dalsgaard A, Albert MJ, Taylor DN et al (1995) Characterization of Vibrio cgolerae non-O1 serogroups obtained from an outbreak of diarrhea in Lima, Peru. J Clin Microbiol 33:2715\u20132722","journal-title":"J Clin Microbiol"},{"key":"794_CR38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/339394a0","volume":"339","author":"VK Chaudhary","year":"1989","unstructured":"Chaudhary VK, Queen C, Junghans RP et al (1989) A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339:394\u2013397","journal-title":"Nature"},{"key":"794_CR39","doi-asserted-by":"crossref","first-page":"8616","DOI":"10.1073\/pnas.88.19.8616","volume":"88","author":"U Brinkmann","year":"1991","unstructured":"Brinkmann U, Pai LH, FitzGerald DJ et al (1991) B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA 88:8616\u20138620","journal-title":"Proc Natl Acad Sci USA"},{"key":"794_CR40","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/pro.5560030805","volume":"3","author":"DJ Matthews","year":"1994","unstructured":"Matthews DJ, Goodman LJ, Gorman CM et al (1994) A survey of furin substrate specificity using substrate phage display. Protein Sci 3:1197\u20131205","journal-title":"Protein Sci"},{"key":"794_CR41","doi-asserted-by":"crossref","first-page":"21791","DOI":"10.1016\/S0021-9258(20)80612-7","volume":"268","author":"AG Zdanovsky","year":"1993","unstructured":"Zdanovsky AG, Chiron M, Pastan I et al (1993) Mechanism of action of Pseudomonas exotoxin. Identification of a rate-limiting step. J Biol Chem 268:21791\u201321799","journal-title":"J Biol Chem"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0794-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-009-0794-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0794-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:28:00Z","timestamp":1634257680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-009-0794-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,29]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1007\/s00262-009-0794-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,29]]}}}